VRCA

– Analysis shows YCANTH achieved complete clearance of molluscum contagiosum approximately 4 times faster than vehicle, regardless of disease duration – WEST CHESTER, Pa., Sept.

– Post-hoc analysis shows YCANTH ® drove high rates of complete clearance in molluscum contagiosum patients regardless of disease duration –

The COVE-2 trial follows a previously completed Phase II trial that had shown a decline in the number of common warts.

Verrica Pharmaceuticals (NASDAQ:VRCA) reported second-quarter revenue growth in its YCANTH treatment for molluscum contagiosum, while outlining progress in pivotal studies of the product for common warts and announcing a credit facility that management said could extend its cash runway into 2028.

Verrica Pharmaceuticals (VRCA) delivered earnings and revenue surprises of +14.29% and +1.77%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

– Company reports record demand for YCANTH® as dispensed applicator units grew to 19,626 in Q2 2026, up 28.3% over the previous quarter and 46.1% year-over-year – – Topline data from global Phase 3 program studying common warts currently expected in mid-2027 – – The Company’s cash runway could extend into 2028 based on its current operating plan and assuming full availability of its new credit facility – – Company reports total revenue of $5.9 million in Q2 2026, including U.S.

— Facility will support YCANTH® commercialization, global Phase 3 program for YCANTH® in common warts and general corporate operations — — Facility provides potential for no scheduled interest or principal payments until maturity in December 2030 — — Facility provided by an entity controlled by Paul B.

WEST CHESTER, Pa., July 30, 2026 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc.

WEST CHESTER, Pa., July 21, 2026 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc.